Navigation Links
Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies
Date:4/21/2009

tatements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to the risk that results from future preclinical studies and clinical trials will not correlate with the results of these preclinical studies, the risk that the fully human antibodies will not provide comparable results in combination with other cancer therapies and the risk that the Company will experience delays in enrolling patients in its existing and planned clinical studies. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2008 and the quarterly report on Form 10-Q for the quarter ended January 31, 2009. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise an
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
2. Alimera Sciences Iluvien(TM) Phase 3 Studies for DME Pass Final DSMB Review Prior to October Readout
3. Cynosure Announces Presentation of Favorable Results from Post-Marketing Studies of Smartlipo MPX
4. Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack
5. Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-211, Potent Small Molecule for Treatment of Schizophrenia.
6. Studies Show Combination Laser Therapy Effective At Clearing Acne, Reducing Oil Production
7. Prescient Medical Achieves Milestones in Clinical Studies of vProtect(TM) Luminal Shield
8. Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM)
9. BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine
10. Oridion Announces Significant Medical Studies Presented at STA
11. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015   Leatt Corporation  (OTCQB: LEAT), ... equipment for all forms of sports, including extreme motor ... brace, announced today that the UISP Lega Motociclismo Lombardia, ... all riders to wear a neck brace during its ...
(Date:1/23/2015)... January 23, 2015 Heptares Therapeutics, the clinical-stage ... announce that the Malcolm Campbell Memorial Prize for ... President of Chemistry), Fiona Marshall (Chief Scientific Officer ... and co-founder) for the seminal contributions to GPCR drug discovery ...
(Date:1/22/2015)... MINNEAPOLIS, Jan. 22, 2015  Uroplasty, Inc. (NASDAQ: UPI ... markets innovative proprietary products to treat voiding dysfunctions, today ... ended December 31, 2014.  Global revenue for the ... $4.4 million, a new quarterly revenue record, as compared ...
Breaking Medicine Technology:Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18
... /PRNewswire-Asia-FirstCall/ -- China Medicine Corporation (OTC Bulletin Board: ... manufacturer, developer and distributor of Western pharmaceuticals, traditional ... the People,s Republic of China, today announced that ... to stockholder approval, the 2011 Long-Term Incentive Plan ...
... N.C., March 3, 2011 Recent ... Corporate governance changes announced Term loan repaid ... Fourth quarter 2010 financial results announced ... CSA ), healthcare,s preferred real estate partner, is a REIT ...
Cached Medicine Technology:China Medicine Corporation Adopts New Incentive Compensation Plans 2China Medicine Corporation Adopts New Incentive Compensation Plans 3Cogdell Spencer Announces Fourth Quarter 2010 Results and Completion of Strategic Plan 2Cogdell Spencer Announces Fourth Quarter 2010 Results and Completion of Strategic Plan 3Cogdell Spencer Announces Fourth Quarter 2010 Results and Completion of Strategic Plan 4Cogdell Spencer Announces Fourth Quarter 2010 Results and Completion of Strategic Plan 5Cogdell Spencer Announces Fourth Quarter 2010 Results and Completion of Strategic Plan 6Cogdell Spencer Announces Fourth Quarter 2010 Results and Completion of Strategic Plan 7Cogdell Spencer Announces Fourth Quarter 2010 Results and Completion of Strategic Plan 8Cogdell Spencer Announces Fourth Quarter 2010 Results and Completion of Strategic Plan 9Cogdell Spencer Announces Fourth Quarter 2010 Results and Completion of Strategic Plan 10Cogdell Spencer Announces Fourth Quarter 2010 Results and Completion of Strategic Plan 11Cogdell Spencer Announces Fourth Quarter 2010 Results and Completion of Strategic Plan 12Cogdell Spencer Announces Fourth Quarter 2010 Results and Completion of Strategic Plan 13Cogdell Spencer Announces Fourth Quarter 2010 Results and Completion of Strategic Plan 14Cogdell Spencer Announces Fourth Quarter 2010 Results and Completion of Strategic Plan 15Cogdell Spencer Announces Fourth Quarter 2010 Results and Completion of Strategic Plan 16
(Date:1/22/2015)... the premier women’s dress supplier, has recently released its ... of AngelWeddingDress.com to find more details. , Many ... a bridal party. AngelWeddingDress offers a variety of gorgeous ... wedding dresses are specially designed for 2015. , AngelWeddingDress ...
(Date:1/22/2015)... 22, 2015 Autocarinsurancebest.com has released a new ... commercial auto insurance policy . , Auto insurance quotes ... It is no longer necessary to call an agent or ... available online on a single website: http://autocarinsurancebest.com/ . , ...
(Date:1/22/2015)... 22, 2015 Yesterday, Senator Holly ... and Kristin Olsen (R-Modesto) were honored by the ... advancing biotechnology, biomedical science, medical device and pharmaceutical ... received the “2014 Life Sciences Champion” award from ...
(Date:1/22/2015)... EBSCO Information Services (EBSCO) and ... relationship in an effort to further promote visibility and adoption ... has long made AMA journals available via its subscription services, ... JAMA Network. , Long known as both a ...
(Date:1/22/2015)... VA (PRWEB) January 22, 2015 Step ... power at the Science Museum of Virginia. Wicked Plants, ... , Wicked Plants unearths 75 poisonous, carnivorous and diabolical ... through each room to uncover the biochemical, physical and ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Wicked Plants are taking over the Science Museum of Virginia 2
... Provides Patient Tips For Safe Plastic Surgery Procedures, ... Donda West,rapper Kanye West,s mother, raised questions about the ... death are still emerging,and include concerns over her physician,s ... in a lengthy surgery. "Patients should,be reassured that Donda ...
... & Bar, other partners and donors share in ... the new National,Pediatric Brain Tumor Consortium headquarters, ... in,translational research for exceptional patient care, MEMPHIS, ... and Chili,s Grill & Bar(R) celebrated the national,grand ...
... Following is a statement,by Linda A. Suydam, ... regarding today,s FDA public meeting seeking comments,on a ... of our member companies, CHPA was pleased to ... of expanded consumer,access to medicines. As the leading ...
... Date, WASHINGTON, Nov. 14 The following was,released by the National Kidney Foundation of ... Ball will feature entertainment by the ... of the ... community leaders. Guests will also enjoy cocktails, dinner, ...
... lessening of the drug may ease addiction, research suggests , ... of gradually decreasing levels of nicotine over a number of ... finds. , The study, conducted by researchers at the University ... Medical Center, included 20 adult smokers. They puffed on their ...
... OSS, Netherlands, Nov. 14 Asenapine -- a ... was shown to be,effective and well-tolerated in patients ... in the current issue of the Journal,of Clinical ... Psychiatric Association,s (APA) annual meeting and at the ...
Cached Medicine News:Health News:Guide to Minimizing Your Plastic Surgery Risks 2Health News:St. Jude Celebrates Next Frontier of Finding Cures With Grand Opening of Chili's Care Center 2Health News:St. Jude Celebrates Next Frontier of Finding Cures With Grand Opening of Chili's Care Center 3Health News:St. Jude Celebrates Next Frontier of Finding Cures With Grand Opening of Chili's Care Center 4Health News:Statement From the Consumer Healthcare Products Association on Proposed New 'Third Class' of Medicines 2Health News:Nicotine-Reduced Cigarettes Could Boost Quitting 2Health News:Study Shows Organon's Asenapine Demonstrates Efficacy and Tolerability in Treating Acute Schizophrenia 2Health News:Study Shows Organon's Asenapine Demonstrates Efficacy and Tolerability in Treating Acute Schizophrenia 3Health News:Study Shows Organon's Asenapine Demonstrates Efficacy and Tolerability in Treating Acute Schizophrenia 4
The Valleylab Surgistat II generator provides exceptional performance, reliability, and safety benefits in a compact, easy to use unit....
Lorgnette pinhole occluder...
Maddox rod and occluder...
Black multi-pinhole occluder...
Medicine Products: